The strategic cooperation between the leading enterprises in precision diagnosis and treatment of cardiovascular diseases in China and the leading investment management institutions of cardiovascular diseases hospitals in China will give full play to their advantages in their respective fields, fully docking and indepth cooperation, and be committed to improving the diagnosis and treatment level of cardiovascular diseases, accelerating the promotion and implementation of cutting-edge cardiovascular diagnosis and treatment technologies.
Mr. Yonghui lv, General Manager of RainMed Medical and Mr. Jiansheng Hao, Chairman of Hanxiputai attended and signed the strategic cooperation agreement.
At present, with the increasing proportion and total number of aging population in China, the prevalence of cardiovascular diseases is on the rise. There are more than 20 million coronary heart disease patients and 200 million hypertension patients in China. As a leading enterprise in precise diagnosis and treatment of cardiovascular diseases in China, RainMed Medical continues to create and launch a series of world-leading epoch-making cardiovascular diagnosis and treatment products.
This time, RainMed Medical signs a strategic cooperation with Hanxiputai, a leading Chinese institution focusing on cardiovascular hospital investment management. The two sides will accelerate the large scale clinical application of revolutionary technology, promote the development of precision medicine and benefit more cardiovascular patients through clinical research, equipment admission, cooperative research and development and other measures. In this signing activity, the two sides also deeply discussed the application value of products, smart medical construction, medical insurance services and other contents.
Mr. Yonghui lv, General Manager of RainMed Medical, said that RainMed Medical has independent r&d capabilities for medical device systems. A series of revolutionary products of the company have been widely praised by experts and scholars in the industry. For example, caFFR, an accurate, efficient and simple product, has occupied a leading position in the FFR product market in China. As a top hospital management group in China, Hanxiputai has rich experts and hospital resources. The cooperation with Hanxiputai will certainly promote the clinical application of products and provide opportunities to create a new generation of precision medical products based on market demand.
Mr. Jiansheng Hao, Chairman of Hanxiputai, said that Hanxiputai is committed to building a high-quality cardiovascular health medical service platform, laying out cardiovascular health management business and paying attention to the application of precise cardiovascular disease assessment. RainMed Medical products are competitive. Hanxiputai is looking forward to the in-depth cooperation between the two sides. In the future, the two sides will carry out comprehensive cooperation in clinical research, health management and other fields in Hanxiputai holding hospital, which will accelerate the optimization transformation of Hanxiputai, improve the brand reputation, and build a more perfect medical service system.
In the future, RainMed Medical will continue to strengthen strategic cooperation with industry partners, always adhere to the purpose of "Shaping precision medicine, serving people's health", continue to create and launch the world's leading cardiovascular diagnosis and treatment products, serve clinicians, and escort people's health.
Contacts : Nick Cheng
WhatsApp: +86 13913586004
Head office: NE-31,Northeast District of Nano City, Suzhou City,Jiangsu Province,China